GRTS - グリットスト―ン・オンコロジ― （Gritstone Oncology Inc.）

Results from phase 2/3 GRANITE study to treat patients with metastatic microsatellite stable colorectal cancer are expected in Q4 of 2023. Find out why GRTS stock is a Strong Buy.

https://www.investing.com/news/pro/gritstone-oncology-inc-receives-investment-bank-analyst-rating-update-3046228

Gainers: Arcturus Therapeutics (ARCT) +15%. lululemon athletica (LULU) +11%

Gritstone bio (GRTS) shares gained Tuesday after B. Riley launched its coverage with a Buy rating noting its prospects in messenger RNA technology. Read more here.

Gritstone bio is focused on developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Find out why GRTS stock is a Hold.

Gritstone bio Inc. (NASDAQ:NASDAQ:GRTS) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ETCompany ParticipantsGeorge MacDougall - Director, Investor Relations and Corporate…

Gritstone Oncology press release (GRTS): FY GAAP EPS of -$1.32 beats by $0.10.Revenue of $19.95M (-58.6% Y/Y) beats by $1.36M.Cash, cash equivalents, marketable securities…

-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 --

Gritstone Oncology (GRTS) is scheduled to announce Q4 earnings results on Thursday, March 9th, after market close.The consensus EPS Estimate is -$0.34 and the consensus Revenue Estimate is…

Conference call to begin at 4:30pm ET on March 9 Conference call to begin at 4:30pm ET on March 9

During the last session, Gritstone bio Inc. (NASDAQ:GRTS)’s traded shares were 1.07 million, with the beta value of the company hitting 0.54. At the end of the trading day, the stock’s price was $3.27, reflecting an intraday gain of 8.64% or $0.26. The 52-week high for the GRTS share is $13.45, that puts it down … Following Its 52-Week Low, Gritstone bio Inc. (NASDAQ: GRTS)’S Share Price Rose 47.71% And Its YTD Numbers Fell -74.57% Read More »

Gritstone bio Inc. (NASDAQ:GRTS) price closed lower on Friday, December 16, dropping -4.19% below its previous close. A look at the daily price movement shows that the last close reads $3.58, with intraday deals fluctuated between $3.335 and $3.90. The company’s 5Y monthly beta was ticking 0.56. Taking into account the 52-week price action we … Gritstone bio Inc. (NASDAQ: GRTS): Still A Hot Buy? Read More »

EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco. The presentation will take place on Thursday, January 12, 2023 from 9:45 - 10:25 AM Pacific Time in Elizabethan A conference room.

Gritstone bio (GRTS) surged Tuesday after announcing that the U.S. regulators issued two new patents covering its self-amplifying mRNA vaccine platform technology. Read the full story here.

Gritstone bio Inc. (NASDAQ:GRTS) marked $3.16 per share on Friday, down from a previous closing price of $3.25. While Gritstone bio Inc. has underperformed by -2.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GRTS fell by -70.85%, with highs and lows ranging from $14.42 to […]